STRONTIUM-89 AND PAMIDRONATE IN COMBINED PALLIATIVE THERAPY OF OSTEOBLASTIC-OSTEOLYTIC BREAST CANCER BONE METASTASES

CORRELATION OF F-18 FDG PET WITH MORPHOMETRIC TUMOR RESPONSE AFTER NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED (STAGE III) NON-SMALL CELL LUNG CANCER (NSCLC)

HIGH-DOSE MYELOABLATIVE VERSUS CONVENTIONAL LOW-DOSE RADIOIMMUNOTHERAPY (RIT) OF MANTLE CELL LYMPHOMA (MCL) WITH THE CHIMERIC ANTI-CD20 ANTIBODY C2B8

TRANSFER OF THE HUMAN SODIUM/IODIDE SYMPORTER GENE ENHANCES IODIDE UPTAKE IN MELANOMA CELLS

89SRCL AND 153SMEDTMP RADIOMETABOLIC TREATMENT OF METASTATIC BONE PAIN (MBP) IN PROSTATE CANCER (PC): OUR EXPERIENCE

ROLE OF 3D PET-FDG IN THE MANAGEMENT OF LYMPHOMAS. THE LATIN AMERICAN EXPERIENCE

DOSIMETRY OF REPEATED Y-90-OCTREOTIDE THERAPY OF SOMATOSTATIN RECEPTOR EXPRESSING TUMOURS

THE THERAPEUTIC EFFECTS AND ABSORBED DOSE OF I-131 MIBG IN PATIENTS WITH MALIGNANT PHEOCHROMOCYTOMA.

ALGORITHMS FOR RECRUITING PATIENTS FOR I-131 MIBG THERAPY

BONE PAIN PALLIATION AND MEDULLARY TOXICITY AFTER [SM153]-EDTMP TREATMENT: RELATION TO THE EXTENT OF DISEASE AND DOSIMETRY

OUTCOME PREDICTION OF RADIOIMMUNOTHERAPY OF NON-HODGKIN'S-LYMPHOMA BY FDG-PET

EVALUATION OF SM-153 EDTMP AS A TUMORICIDAL AGENT IN PROSTATE CANCER

RADIOIODINE THERAPY INDUCES DOSE-DEPENDENT IN-VIVO OXIDATION INJURY

THE RELATIONSHIP BETWEEN 99M-TC-MIBI UPTAKES AND TUMOR CELL DEATH/PROLIFERATION STATE UNDER IRRADIATION

131I TREATMENT OF BRAIN METASTASES FROM DIFFERENTIATED THYROID CARCINOMA

131I TREATMENT LIVER METASTASES FROM DIFFERENTIATED THYROID CARCINOMA